Granules India will invest Rs 400 crore over the next two years to backward integrate its key products and set up a greenfield formulation facility near Hyderabad, Telangana.
The company has started work on end-to-end manufacturing of at least two key large-volume molecules.
The backward integration will allow the company to mitigate supply chain disruptions, volatility in prices and also increase expectations of environmental standards.
The company will spend around Rs 250 crore on its backward integration and Rs 150 crore on its greenfield formulation manufacturing unit in Genome Valley, near Hyderabad.
The company is in the midst of capacity expansion which will take its tablet capacity from 23-24bn to around 29bn.